US generics drug major Mylan (Nasdaq: MYL) announced its financial results for the three months ended June 30, 2011 showing that adjusted diluted earnings per share were $0.52, a leap of 40.5% over the like year-earlier quarter. Total revenues of $1.57 billion for the quarter rose 14.6% to $1.37 billion.
On a GAAP basis, diluted EPS of $0.33 for the three months compared to $0.16 for the same prior year period. The company repurchased 14.8 million shares for around $350 million during the second quarter. Consensus forecasts of analysts polled by Thomson Reuters expected EPS of $0.45 on revenues of $1.49 billion.
Sales of generic drugs advanced 17.1% to $1.44 billion from $1.23 billion a year ago, with revenues from North American rising 27.2% to $749.1 million, mainly due to the sale of new products. In Europe, sales rose slightly, to $378.7 million from $378 million. Foreign currency exchange had a positive impact on sales, reflecting the weakening of the US dollar against the euro.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze